# Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

Study · id `cardio:ct-nct01462266` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01462266](<https://clinicaltrials.gov/study/NCT01462266>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01462266

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 660 participants.

## Technical summary

Registry record NCT01462266. Randomized; double masking; primary purpose treatment. Start 2012-01-13 (actual); primary completion 2013-06-06 (actual). Results posted on 2014-04-08.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 660 participants (enrolled count; ClinicalTrials.gov record NCT01462266, source copy `cardio:ctgov-nct01462266-2018-08-17`, retrieved 2026-10-26)
- Started: 2012-01-13 (actual) (ClinicalTrials.gov record NCT01462266, source copy `cardio:ctgov-nct01462266-2018-08-17`, retrieved 2026-10-26)
- Primary completion: 2013-06-06 (actual) (ClinicalTrials.gov record NCT01462266, source copy `cardio:ctgov-nct01462266-2018-08-17`, retrieved 2026-10-26)
- Completion: 2013-06-07 (actual) (ClinicalTrials.gov record NCT01462266, source copy `cardio:ctgov-nct01462266-2018-08-17`, retrieved 2026-10-26)
- Results first posted: 2014-04-08 (ClinicalTrials.gov record NCT01462266, source copy `cardio:ctgov-nct01462266-2018-08-17`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01462266-2018-08-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Comparator: Placebo
- Intervention (Biological): Insulin Glargine
- Intervention (Drug): Metformin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 6a763d476f59f192c15d2d89f781f3a6efea12fc8d0e673a7b36a5d1f2759952
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
